M

Malin Corporation PLC
ISEQ:MLC

Watchlist Manager
Malin Corporation PLC
ISEQ:MLC
Watchlist
Price: 8.65 EUR Market Closed
Market Cap: 162.7m EUR
Have any thoughts about
Malin Corporation PLC?
Write Note

Malin Corporation PLC
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Malin Corporation PLC
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
M
Malin Corporation PLC
ISEQ:MLC
Interest Income Expense
€2.6m
CAGR 3-Years
-70%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ICON PLC
NASDAQ:ICLR
Interest Income Expense
-$259.5m
CAGR 3-Years
-25%
CAGR 5-Years
-112%
CAGR 10-Years
N/A
No Stocks Found

Malin Corporation PLC
Glance View

Market Cap
164.1m EUR
Industry
Life Sciences Tools & Services

Malin Corp. Plc.invests and supports innovative life sciences companies, which develops exceptional science and technology to deliver transformative outcomes for patients. The company is headquartered in Dublin, Dublin and currently employs 5 full-time employees. The company went IPO on 2015-03-25. The Company’s assets give investors access to life sciences businesses with exposure across diverse modalities, therapeutic areas and geographies. Its business includes Poseida, Viamet, Xenex, CG Oncology, Wren, KNOW Bio and Artizan. Poseida is a clinical-stage biopharmaceutical company building a pipeline of Chimeric antigen receptor T cell (CAR-T) product candidates, initially focused on the treatment of hematological malignancies, including multiple myeloma, and solid tumours, like prostate cancer. The company is also developing two CAR-T therapies: autologous and allogeneic. Xenex is a commercial-stage medical device company focused on reducing healthcare-associated infections with its non-mercury, full-spectrum disinfection LightStrike Germ-Zapping robots. CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder-saving therapeutics for patients with bladder cancer.

MLC Intrinsic Value
10.81 EUR
Undervaluation 20%
Intrinsic Value
Price
M

See Also

What is Malin Corporation PLC's Interest Income Expense?
Interest Income Expense
2.6m EUR

Based on the financial report for Jun 30, 2024, Malin Corporation PLC's Interest Income Expense amounts to 2.6m EUR.

What is Malin Corporation PLC's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
-70%

Over the last year, the Interest Income Expense growth was -86%. The average annual Interest Income Expense growth rates for Malin Corporation PLC have been -70% over the past three years .

Back to Top